Floatz logo

Therapeutic Asset Ratings

18,135 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cyclophosphamide
Rectal Carcinoma
University Hospital, GenevaP2BB (67)
Cyclophosphamide
Rectal Cancer
Essen BiotechP2BB (67)
Cyclophosphamide
Soft Tissue Sarcoma
St. Jude Children's Research HospitalP2BB (67)
Cyclophosphamide
Smoldering Plasma Cell Myeloma
Dana-Farber Cancer InstituteP2BB (67)
Cyclophosphamide
Squamous Cell Carcinoma
Diwakar DavarP2BB (67)
Cyclophosphamide
Synovial Sarcoma
Zelluna Immunotherapy ASP2BB (67)
Cyclophosphamide
Thymic Carcinoma
Beijing BiotechP2BB (67)
Cytarabine
Hematopoietic And Lymphoid Cell Neoplasm
Senti BiosciencesP2BB (67)
Dalzanemdor
Cognitive Disorder
Supernus Pharmaceuticals, Inc.P2BB (67)
Dexasone
Chromosome 17p Deletion
Fondazione EMN Italy OnlusP2BB (67)
Docetaxel
Metastatic Melanoma
OncoC4, Inc.P2BB (67)
Fludarabine
Pancreatic Ductal Adenocarcinoma
Beijing BiotechP2BB (67)
Fludarabine
Multiple Sclerosis
Indapta Therapeutics, INC.P2BB (67)
Fludarabine
Acquired Polycythemia Vera
Thomas Jefferson UniversityP2BB (67)
Irinotecan
Biliary Tract Cancer
Shenzhen Xinhe BiomedicalP2BB (67)
Irinotecan
Endometrial Carcinoma
Whitehawk Therapeutics, Inc.P2BB (67)
Irinotecan
Esophageal Cancer
Neonc Technologies, Inc.P2BB (67)
Irinotecan
Osteosarcoma
Milton S. Hershey Medical CenterP2BB (67)
Irinotecan
Mycosis Fungoides
Virogen Biotechnology Inc.P2BB (67)
Irinotecan
Wilms Tumor
Centre Oscar LambretP2BB (67)
Letrozole
Endometrial Carcinoma
Avenzo Therapeutics, Inc.P2BB (67)
Letrozole
Progesterone-Receptor Positive Breast Cancer
Ruth O'ReganP2BB (67)
Letrozole
Triple-Negative Breast Carcinoma
NiKang Therapeutics, Inc.P2BB (67)
Maralixibat
Alagille Syndrome
Mirum Pharmaceuticals, Inc.P2BB (67)
Methotrexate
Chemotherapy-Induced Toxicity
Instituto do Cancer do Estado de São PauloP2BB (67)
Showing 3301 to 3325 of 18,135 assets
PreviousPage 133 of 726Next